Proton Therapy News, Insights and Education.

Mevion and FLASH Therapy

At the first virtual meeting of the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, Mevion presented its research and development progress demonstrating the FLASH effect on commercially available MEVION S250i compact proton accelerators on Tuesday, October 27th in the Innovation Hub.

The presentation recording is now available on-demand. 

FLASH Therapy*, a non-invasive, ultra-high dose rate delivered at incredible speeds, may dramatically improve the cancer-fighting benefits of therapeutic radiation by shortening treatment courses and lessening side effects.

When compared to more traditional cancer treatments, FLASH Therapy has been shown to spare healthy, normal tissue instead of damaging it. There is also evidence that FLASH Therapy kills cancerous cells and spares patients from some of the more uncomfortable and invasive physical side effects of traditional cancer treatments.

Driven by innovation and guided by a coalition of clinical partners and FLASH thought leaders, Mevion’s Advanced Development team has yielded strong results from an initial small animal study that could propel this potentially promising cancer treatment forward.

In this talk, you will learn about Mevion's progress on: 
  • Mevion and the future of FLASH 
  • FLASH Research Platform Development 
  • First FLASH Results from Small-Animal Studies on MEVION S250i Research Platform
  • Why the Mevion system is well-suited for FLASH delivery when clinical FLASH becomes a reality

This talk recording will give you insight into understanding Mevion's history that will help shape our future. You will also learn about Mevion's progressive technology development, current plans, and recent research using the MEVION S250i research platform. 

Watch the talk recording now: 


Don't miss our many upcoming virtual events! And check out the Mev-Ionosphere blog today for more proton therapy updates. 

*FLASH Therapy is currently under preclinical research and is not yet available for commercial sale or clinical use.

Get our blog delivered to your inbox. Subscribe here.